Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069738 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
A NA study of Heart Failure - NYHA II - IV, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 850
- Enrollment target
- 18
- Study locations
NCT07069738: Recruiting NA study of Heart Failure - NYHA II - IV, sponsored by Boston Scientific Corporation.
NCT07069738 is a NA study of Heart Failure - NYHA II - IV that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 850 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07069738, a NA study of Heart Failure - NYHA II - IV, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 850 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT). 2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Primary Outcome
The primary effectiveness endpoint is a composite of reduction in all-cause mortality, heart transplant, left ventricular assist device (LVAD), time to first heart failure (HF) events, time to first ventricular tachycardia (VT) / ventricular fibrillation (VF) requiring device therapy or external defibrillation/cardioversion.
Conditions Studied
Interventions
- DEVICE CRT-D with a Quadripolar LV lead
- DEVICE CRT-D with INGEVITY+ pace/sense lead
Study Locations (18)
New York
- New York Hospital Queens - Flushing
- Weill Cornell Medical University - New York
- Rochester General Hospital - New York
Alabama
- Heart Center Research, LLC - Huntsville
- Mobile Infirmary Medical Center - Mobile
California
- Alta Bates Summit Medical Center - Oakland
- Cardiology Associates Medical Group, Inc. - Ventura
Minnesota
- St. Mary's Duluth Clinic Regional Heart Center - Duluth
- Centracare Heart and Vascular Center - Saint Cloud
Arkansas
- Arrhythmia Research Group - Jonesboro
Florida
- Sarasota Memorial Hospital - Sarasota
Georgia
- Emory University Hospital - Atlanta
Illinois
- Midwest Cardiovascular Institute - Naperville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2029-11 |
| Phase | NA |
What NCT07069738 shows while recruiting
NCT07069738 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Heart Failure - NYHA II - IV appearing as the primary indexed condition, and to 2 interventions - of which CRT-D with a Quadripolar LV lead is the first listed.
NCT07069738 lists 18 locations in 13 states (New York, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT07069738 about?
NCT07069738 is a clinical study titled "Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure". This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardi...
What is the current status of trial NCT07069738?
This trial is currently recruiting. It is a NA study. The enrollment target is 850 participants. The study started on 2025-10-22. Estimated completion is 2029-11.
What conditions does trial NCT07069738 study?
This clinical trial studies the following conditions: Heart Failure - NYHA II - IV.
What interventions are being tested in trial NCT07069738?
The interventions under investigation include: CRT-D with a Quadripolar LV lead (DEVICE), CRT-D with INGEVITY+ pace/sense lead (DEVICE).
Who is sponsoring clinical trial NCT07069738?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069738 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure - NYHA II - IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07069738's enrollment target sits among peer trials
850 131st of 2000 higher than 1,870 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06289673 · 850 participants · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI